We report 2 cases of parakeratosis variegata (PV) evolving from lesions beginning with characteristics of ashy dermatosis. Both patients presented with a reticulated, poikilodermatous and hyperpigmented eruption with bizarre coalescent lichenoid papules. Histology showed lichenoid epidermotropic infiltrates, more pronounced in case No. 1, consistent with early malignancy. The course was chronic: after more than 10 years, systemic symptoms were not present. In patient No. 1, a monoclonal T-cell population was detected 12 years after the onset of the disease. Both patients had close contact with fertilizers and insecticides. In patient No. 2, the lesions spontaneously regressed within 3 years after cessation of exposure. PV may be a prelymphomatous stage of mycosis fungoides or some closely related cutaneous T-cell lymphoma and does not always evolve into overt malignancy. Gene rearrangement detection techniques may be helpful in predicting the course of the disease.

Unna PG, Santi F, Pollitzer D: Über die Parakeratosen im allgemeinen und eine neue Form derselben (Parakeratosis variegata). Monatschr Prakt Dermatol 1890;10:404–412.
Brocq L: Les parapsoriases. Ann Dermatol Syphiligr (Paris) 1902;3:433–468.
Burg G: Small plaque (digitate) parapsoriasis is an ‘abortive cutaneous T-cell lymphoma’ and is not mycosis fungoides. Arch Dermatol 1995;131:336–338.
Sanchez JL, Ackerman AB: The patch stage of mycosis fungoides: Criteria for histologic diagnosis. Am J Dermatopathol 1979;1:5–26.
Ackerman AB: If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an ‘abortive’ one, it must be mycosis fungoides! Arch Dermatol 1996;132:562–566.
Lambert WC, Everett MA: The nosology of parapsoriasis. J Am Acad Dermatol 1981;5:373–395.
Dommann S, Zimmermann D, Zimmermann-Dours MT, Kung E, Burg G: Extracutaneous clonal TCR-beta rearrangement on cutaneous T-cell lymphoma (CTCL) and pseudolymphomas (PSL). Arch Dermatol Res 1994;286:218.
Haeffner AC, Smoller BR, Zepter K, Wood GS: Differentiation and clonality of lesional lymphocytes in small plaque parapsoriasis. Arch Dermatol 1995;131:321–324.
Weiss LM, Wood GS, Ellisen LW, Reynolds TC, Sklar J: Clonal T-cell populations in pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease). Am J Pathol 1987;126:417–421.
Panhans A, Bodemer C, Macinthyre E, Fraitag S, Paul C, de Prost Y: Pityriasis lichenoides of childhood with atypical CD30-positive cells and clonal T-cell receptor gene rearrangement. J Am Acad Dermatol 1996;35:489–490.
Rivers JK, Samman PD, Spittle M, Smith NP: Pityriasis lichenoides-like lesions associated with poikiloderma atrophicans vasculare. Br J Dermatol 1986;115(suppl 30):17.
Watzig V, Roth H: Parakeratosis variegata. Dermatol Monatschr 1984;170:683–688.
Kikuchi A, Naka W, Nishikawa T: Cutaneous T-cell lymphoma arising from parakeratosis variegata: Long-term observation with monitoring of T-cell receptor gene rearrangement. Dermatology 1995;190:124–127.
Curco N, Servitje O, Llucia M, Bertran J, Limon A, Carmona M, Romagosa V, Peyri J: Genetic analysis of cutaneous T-cell lymphoma: A comparative study of Southern blot analysis with polymerase chain reaction amplification of the T-cell receptor-gamma gene. Br J Dermatol 1997;137:673–679.
Ryan DK, Alexander HD, Morris TCM: Routine diagnosis of large granular lymphocytic leukaemia by Southern blot and polymerase chain reaction analysis of clonal T cell receptor gene rearrangement. J Clin Pathol Mol Pathol 1997;50:77–81.
Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK: Parakeratosis variegata; in Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK (eds): Dermatology. London, Springer, 1991, p 444.
Grice K, Smith N: Pityriasis lichenoides with poikiloderma atrophicans vasculare. Br J Dermatol 1980;103:66–67.
Fortson JS, Schroeter AL, Esterly NB: Cutaneous T-cell lymphoma (parapsoriasis en plaque). Arch Dermatol 1990;126:1449–1453.
Kiene P, Fölster-Holst R, Mielke V: Parakeratosis variegata nach Pityriasis lichenoides et varioliformis acuta. Hautarzt 1995;46:498–501.
Niemczyk UM, Zollner TM, Wolter M, Staib G, Kaufmann R: The transformation of pityriasis lichenoides chronica into parakeratosis variegata in an 11-year-old girl. Br J Dermatol 1997;137:983–987.
Weinberg JM, Rook AH, Lessin SR: Molecular diagnosis of lymphocytic infiltrates of the skin. Arch Dermatol 1993;129:1491–1500.
Muche JM, Lukowsky A, Asadullah K, Gellrich S, Sterry W: Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T cell lymphoma. Blood 1997;90:1636–1642.
Popp C, Bacharach-Buhles M, Sterry W, Griesser H, Altmeyer P: Überlegungen zur Pathogenese der Parakeratosis variegata anhand morphologischer und moleculargenetischer Befunde. Hautarzt 1992;43:634–639.
Jablonska S: Ingestion of ammonium nitrate as a possible cause of erythema dyschromicum perstans (ashy dermatosis). Dermatology 1975;150:287–291.
Fischman AB, Bunn PA, Guccione JG, Matthews MJ, Minna JD: Exposure to chemicals, physical agents, and biological agents in mycosis fungoides and the Sézary syndrome. Cancer Treat Rep 1979;63:591–596.
Cohen SR, Stenn KS, Braverman IM: Mycosis fungoides: Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 1980;46:2654–2666.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.